{"entity":{"id":"binding-presentation-recognition","kind":"term","name":"Peptide binding, presentation and immune recognition","aka":[],"tldr":"A peptide can bind a display molecule, be displayed by a cell, or be recognized by an immune receptor. These are different questions that require different evidence.","summary":"Binding prediction estimates one part of antigen selection. Immunopeptidomics examines peptides recovered with HLA molecules, while immune assays investigate receptor binding and functional responses. A primary melanoma study directly identified naturally presented mutated peptides and separately tested their immunogenicity. A consortium study likewise evaluated prediction against measured immune interactions. A candidate supported at one stage should retain that evidence level rather than being described as a demonstrated therapeutic target.","asOf":"2026-11-09","links":[{"label":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.","url":"https://doi.org/10.1038/ncomms13404"},{"label":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.","url":"https://doi.org/10.1016/j.cell.2020.09.015"},{"label":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data.","url":"https://doi.org/10.4049/jimmunol.1700893"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1093/nar/gkaa379"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1038/s41596-019-0133-y"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1126/science.274.5284.94"}],"tags":[],"related":["neoantigen","immunopeptidome","peptide-hla-binding-prediction","peptide-hla-multimer-staining","immune-cytotoxicity-assays"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Peptide-to-HLA binding and TCR-to-peptide-HLA binding are different contacts. Evidence maps to claims: a binding prediction supports a model estimate for one exact peptide and allele (Reynisson et al., 2020, PMID 32406916); measured binding supports binding under that assay; immunopeptidomics supports association with the recovered preparation (Purcell et al., 2019, PMID 31092913), not guaranteed cancer-cell origin, surface location or complete recovery; peptide-HLA multimer staining shows cells binding a defined reagent (Altman et al., 1996, PMID 8810254), not affinity or killing; only a controlled response to naturally presenting target cells supports recognition or the measured function. Supplied-peptide stimulation can bypass processing, and secretion and target-cell death are different outputs."],"category":"Immunology"},"route":"/terms/binding-presentation-recognition/","neighbours":{"term":[{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immune-cytotoxicity-assays","kind":"term","name":"Immune-cell cytotoxicity assays","route":"/terms/immune-cytotoxicity-assays/"},{"id":"immunogenicity-versus-efficacy","kind":"term","name":"Immunogenicity and clinical efficacy","route":"/terms/immunogenicity-versus-efficacy/"},{"id":"immunopeptidome","kind":"term","name":"Immunopeptidome","route":"/terms/immunopeptidome/"},{"id":"immunopeptidomics","kind":"term","name":"Immunopeptidomics","route":"/terms/immunopeptidomics/"},{"id":"multi-epitope-constructs","kind":"term","name":"Multi-epitope constructs and antigen processing","route":"/terms/multi-epitope-constructs/"},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/"},{"id":"peptide-hla-binding-prediction","kind":"term","name":"Peptide-HLA binding and ligand prediction","route":"/terms/peptide-hla-binding-prediction/"},{"id":"peptide-hla-multimer-staining","kind":"term","name":"Peptide-HLA multimer staining","route":"/terms/peptide-hla-multimer-staining/"},{"id":"self-similarity-immune-recognition","kind":"term","name":"Self-similarity and immune-recognition specificity","route":"/terms/self-similarity-immune-recognition/"}],"pathway":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/"}]}}